UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2015

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission File Number: 333-173873

 

               Med-Cannabis Pharma, Inc.                      

 (Exact name of registrant as specified in its charter)

 

Nevada	45-0704149
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

 

817 NW Hill Street Bend, OR 97701

 (Address of principal executive offices)

 

  Tel: (214) 666-8364

 (Registrant’s telephone number, including area code)

 

NA 

 (Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

 

Large Accelerated Filer ☐	Accelerated Filer  ☐
Non-Accelerated Filer ☐  Do not check if a smaller reporting company)	Smaller Reporting Company  ☒

  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes No x

 

The number of shares outstanding of the Registrant's common stock, $0.0001 par value, as of August 12, 2015, was 50,220,000.

 

 

 

TABLE OF CONTENTS

 

Item				Page
PART I – FINANCIAL INFORMATION				4
	Item 1	Financial Statements		4
	Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15
	Item 3	Quantitative and Qualitative Disclosures About Market Risk		20
	Item 4	Controls and Procedures		20
PART II – OTHER INFORMATION				22
	Item 1	Legal Proceedings		22
	Item 1A	Risk Factors		22
	Item 2	Unregistered Sales of Equity Securities and Use of Proceeds		22
	Item 3	Defaults Upon Senior Securities		22
	Item 4	Mine Safety Disclosures		22
	Item 5	Other Information		22
	Item 6	Exhibits		22
Signatures				23

 

 

 

 

 

 

  

Forward-Looking Statements

 

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements of the Registrant to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Registrant’s plans and objectives are based, in part, on assumptions involving it continuing as a going concern and executing on its stated business plan and objectives. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Registrant. Although the Registrant believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Registrant or any other person that the objectives and plans of the Registrant will be achieved.

 

As used in this Quarterly Report, the terms "we", "us", "our", "Med-Cannabis Pharma", “Registrant”, and “Issuer” refers to Med-Cannabis Pharma, Inc. unless the context clearly requires otherwise.

 

 

 

 

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 MED-CANNABIS PHARMA, INC.

CONSOLIDATED BALANCE SHEETS

As of June 30, 2015 and

December 31, 2014

 

 

ASSETS
			6/30/2015						12/31/2014
			(unaudited)						(audited)
Current assets:
Cash and equivalents		$	27,506			$			14,763
Accounts receivable			10,000						—
Other receivables			83,300						—
Total current assets			121,306						14,763
Fixed assets (net)			31,634						—
Other assets			2,711						—
Total assets:		$	155,651			$			14,763
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
Current liabilities:
Accounts payable		$	6,802				$	6,285
Accounts payable – related party			40,526					—
Accrued expenses			6,042					26,333
Accrued expenses – related party			11,231					—
Deferred revenue			—					5,000
Notes payable to stockholders			692,227					323,579
			756,828					361,197
Total liabilities		$	756,828				$	361,197
Stockholders’ (deficit):
Preferred stock, $0.0001 par value, 25,000,000 shares authorized; no shares issued and outstanding			—					—
Common stock, $0.0001 par value, 500,000,000 shares authorized; 50,220,000 and 50,170,000 shares issued and outstanding, respectively			5,022					5,017
Additional paid-in capital			59,381,818					59,066,823
Accumulated Deficit			(59,988,017	)				(59,418,274		)
Total stockholders’ (deficit)		$	(601,177	)			$	(346,434		)
Total liabilities and stockholders’ (deficit)		$	155,651				$	14,763

 

  

The accompanying notes to the financial statements are an integral part of these statements.

 

 

 

MED-CANNABIS PHARMA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

For The Six and Three Months Ended June 30, 2015 and 2014

(unaudited)

 

 

			For the three months ended June 30,										For the six months ended June 30,
			2015				2014						2015				2014
Revenues, net			10,000			$	—					$	10,000			$	—
Cost of revenues			9,231				—						9,231				—
Gross profit			769				—						769				—
Expenses:
Depreciation and amortization			7,711				—						7,711
General and administrative			68,206				40,612						190,827				43,640
Consulting fees			12,588				1,869						328,493				2,119
Legal Fees			8,613				5,003						8,613				12,578
Accounting fees			9,785				3,000						10,785				4,000
Transfer agent fees			—				1,731						931				2,103
Total Expenses			106,903				52,215						547,360				64,440
(Loss) from operations			(106,134	)			(52,215	)					(556,591	)			(64,440	)
Other income (expense)
Interest expense			(14,337	)			(2,655	)					(23,152	)			(4,109	)
Total other income (expense)			(14,337	)			(2,655	)					(23,152	)			(4,109	)
Provision for income taxes			—				—						—				—
Net (loss)			(120,471	)		$	(54,870	)				$	(569,743	)		$	(68,549	)
(Loss) per common share, basic and diluted			**				**						(0.01	)			**
Weighted average number of common shares outstanding, basic and diluted			50,220,000				210,000,000						50,213,094				210,000,000
** Less than $0.01

 

The accompanying notes to the financial statements are an integral part of these statements.

 

 

 

MED-CANNABIS PHARMA, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ (DEFICIT)

For The Three Month Period Ended June 30, 2015 and

The Year Ended December 31, 2014

(Unaudited)

 

 

			Common Stock								Paid-in				Accumulated
			Shares				Amount				Capital				Deficit				Totals
Balance, December 31, 2013			210,000,000			$	21,000			$	59,014,061			$	(59,105,772	)		$	(70,711	)
Cancellation of shares of common stock			(159,930,000	)			(15,993	)			15,993				—				—
Forgiveness of debt			—				—				1,806				—				1,806
Issuance of shares of common stock to consultant			100,000				10				29,990				—				30,000
Imputed interest on related party loan			—				—				4,973				—				4,973
Net (loss) for the period			—				—				—				(312,502	)			(312,502	)
Balance, December 31, 2014			50,170,000			$	5,017			$	59,066,823			$	(59,418,274	)		$	(346,434	)
Issuance of shares of common stock for services			50,000				5				14,995				—				15,000
Donated Capital			—				—				300,000				—				300,000
Net (loss) for the period			—				—				—				(449,272	)			(569,743	)
Balance, June 30, 2015 (unaudited)			50,220,000				5,022				59,381,818				(59,988,017	)			(601,177	)

 

 

The accompanying notes to the financial statements are an integral part of these statements.

 

 

  

MED-CANNABIS PHARMA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For The Six Months Ended June 30, 2015 and 2014

(unaudited)

 

 

		For the six months ended June 30,
		2015				2014
Cash flows from operating activities:
Net (loss)		$	(569,743	)		$	(68,549	)
Adjustments to reconcile net (loss) to net cash provided (used) by operating activities
Depreciation expense			7,711				—
Shares issued for services			15,000				—
Donated capital			300,000				—
Imputed interest on related party loan			—				4,109
Changes in operating assets and liabilities:
Change in accounts receivable			(93,800	)			—
Change in other assets			(2,711	)			(3,000	)
Change in accounts payable			41,043				(9,930	)
Change in accrued expenses			(9,060	)			—
Change in deferred revenue			(5,000	)			—
Net cash provided (used) by operating activities			(316,560	)			(57,510	)
Cash flows from investing activities:
Purchased of fixed assets			(39,345	)			58,656
Net cash (used in) investing activities			(39,345	)			58,656
Cash flows from financing activities:
Increase in notes payable to a stockholder			368,648				—
							1,146
Net cash (used in) financing activities			368,648				—
Net increase (decrease) in cash			12,743				(37	)
Cash – beginning of period			14,763				37
Cash – end of period		$	27,506			$	1,183
Non-cash investing and financing activities:
Cash Paid During Year for Interest Expense			0				0
Shares Issued for Services			15,000				26,000
Cancellation of Common   Shares			0				(30,000	)

 

 

The accompanying notes to the financial statements are an integral part of these statements.

 

 

MED-CANNABIS PHARMA, INC.

June 30, 2015

(unaudited)

 

 

NOTE 1 – Summary of Significant Accounting Policies

 

Unaudited Interim Financial Information

 

The accompanying Consolidated Balance Sheet as of June 30, 2015 and December 31, 2014, Consolidated Statements of Operations for the three and six months ended June 30, 2015, Consolidated Statement of Stockholder’s (Deficit) and the Consolidated Statements of Cash Flows for the six months ended June 30, 2015 are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles accepted in the United States of America (“GAAP”). In the opinion of the company’s management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and included all adjustments necessary for the fair presentation of the Company’s statement of financial position at June 30, 2015 and its results of operations and its cash flows for the period ended June 30, 2015. The results for the period ended June 30, 2015 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2015.

 

Organization

 

Med-Cannabis Pharma, Inc. (“Company” or “Med-Cannabis Pharma”) was incorporated under the laws of the State of Nevada on February 23, 2011. Med-Cannabis Pharma has three subsidiaries, two which are wholly owned: Medical Management Systems, Inc. which has operations as of June 30, 2015 and has begun to record revenue and Med-Pharma Management, Inc. which has no operations as of June 30, 2015 and has not recognized an revenue. The Company’s other subsidiary is a joint venture, High Desert MMJ, Inc. where the Company owns 99%. High Desert MMJ did not have any sales as of June 30, 2015 but did incur set-up costs for the Company’s ‘grow’ operation.,

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (US GAAP) for financial information and in accordance with the Securities and Exchange Commission’s (SEC) Regulation S-X. They reflect all adjustments which are, in the opinion of the Company’s management, necessary for a fair presentation of the financial position and operating results as of and for the period ended June 30, 2015.

 

Use of Estimates

 

The accompanying financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgment. Actual results may vary from these estimates.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. As of June 30, 2015, the Company had $ 27,506 in cash and equivalents and $14,763 at December 31, 2014.

 

 

  

Investments

 

The Company accounts for its marketable securities, which are classified as trading securities, in accordance with generally accepted accounting principles for certain investments in debt and equity securities, which requires that trading securities be carried at fair value. Unrealized gains and losses due to changes in fair value as well as realized gains and losses resulting from sales of securities are reported as Other Income/Expenses in the statement of operations. Fair value of the securities is based upon quoted market prices in active markets or estimated fair value when quoted market prices are not available. The cost basis for realized gains and losses is determined on a specific identification basis. As of June 30, 2015 the Company had no investments.

 

Fair Value of Financial Instruments

 

ASC 820, “Fair Value Measurements” and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

 

Level		Description
Level 1		Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2		Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3		Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The estimated fair values of the Company’s financial instruments are as follows:

 

  

		Fair Value Measurement at June 30, 2015 Using:
Description			6/30/15		Quoted Prices In Active Markets For Identical Assets  (Level 1)		Significant Other Observable Inputs  (Level 2)		Significant Unobservable Inputs  (Level 3)
Assets
	Cash and equivalents	$	27,506	$	27,506	$	-	$	-
		$	27,506	$	27,506	$	-	$	-
Liabilities
	Accounts payable	$	47,328	$	47,328	$	-	$	-
	Accrued expenses		17,273		17,273		-		-
	Note payable to stockholder	$	692,227	$	692,227		-		-

 

 

 

		Fair Value Measurement at December 31, 2014 Using:
Description			12/31/14		Quoted Prices In Active Markets For Identical Assets  (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs  (Level 3)
Assets
	Cash and equivalents	$	14,763	$	14,763	$	-	$	-
		$	14,763	$	14,763	$	-	$	-
Liabilities
	Accounts payable	$	6,285	$	6,285	$	-	$	-
	Accrued Expenses		26,333		26,333
	Deferred Revenue		5,000		5,000		-		-
	Note payable to stockholder	$	323,579	$	323,579	$	-	$	-

  

 

Revenue Recognition

For the quarter ended June 30, 2015, the Company realized $10,000 in revenue and $0 in 2014.

The Company recognizes revenue in accordance with ASC 605-10, "Revenue Recognition in Financial Statements". Revenue will be recognized only when all of the following criteria have been met:

Persuasive evidence of an arrangement exists; · Ownership and all risks of loss have been transferred to buyer, which is generally upon shipment; · The price is fixed and determinable; and · Collectability is reasonably assured.

Revenue is recorded net of any sales taxes charged to customers.

 

Net Loss per Share Calculation

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per shares is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. During the periods ended June 30, 2015 and December 31, 2014 and since inception the Company had no dilutive financial instruments issued or outstanding.

 

 

 

Income Taxes

 

The Company accounts for income taxes pursuant to FASB ASC 740, Income Taxes. Under FASB ASC 740-10-25, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

 

The Company maintains a valuation allowance with respect to deferred tax assets. Med-Cannabis Pharma establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

  

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about its ability to realize the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

 

Fiscal Year

 

The Company elected December 31st for its fiscal year end.

 

NOTE 2 – Going Concern

 

The Company plans to acquire medical marijuana collectives and/or medical marijuana dispensaries, which are currently in operations legally within the states that medical marijuana has been approved and is legal. Currently the Company has existing dispensaries in the state of Oregon. In addition, the Company intends to further expand by opening new medical marijuana collectives and medical marijuana dispensaries in locations where an acquisition is not readily available such as states where medical marijuana has been newly legalized.

While management of the Company believes that Med-Cannabis Pharma will be successful in its planned operating activities under its business plan and capital formation activities, there can be no assurance that it will be able to successfully execute on either of these or that it will be able to generate adequate revenues to earn a profit or sustain its operations.

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United State of America, which contemplate continuation of the Company as a going concern. The Company has not established a source of revenues sufficient to cover its operating costs, and as such, has incurred an operating loss since its inception. Further, as of June 30, 2015, the Company had a working capital deficiency of ($635,522). These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

 

 

 

 

NOTE 3 – Fixed Assets

 

			06/30/15				12/31/14
Grow lights		$	30,845			$	—
Construction-in-process			8,500				—
Gross Fixed Assets			39,345				—
Accumulated depreciation			(7,711	)			—
Net Fixed Assets		$	31,634			$	—

 

The Company purchased $39,345 of fixed assets during the three months ended June 30, 2015, of which $8,500 is CIP (construction-in-process) and the remaining $30,845 was for assets placed in service. Depreciation expense for both the three and six months ended June 30, 2015 was $7,711.

NOTE 4 – Common Stock

 

The total number of common shares authorized that may be issued by the Company is 500,000,000 shares with a par value of $0.0001 per share.

  

On January 15, 2015the Company issued an aggregate of 50,000 shares during the period ending June 30, 2015 for consulting services rendered in conjunction with the evaluation of a new location. The stock was valued at $0.30/share, the closing price on January 15, 2015, the date of the agreement.

 

On July 28, 2014, Big Sky Oil, Inc., the majority shareholder of Med-Cannabis Pharma Inc. (the “Company”), returned to the Company’s treasury 159,930,000 shares of the Company’s common stock it had purchased from prior management. Big Sky agreed to return these shares to the treasury for use in future possible issuances by the Company.

 

During the period ended March 31, 2015 South Beach Live, Inc. transferred 1,000,000 shares of its stock in MCPI to consultants for ongoing services associated with marketing strategies. South Beach Live, Inc. is a related party and does not expect to be repaid for this transaction which was treated as an expense and donated capital by MCPI.

 

During the period ending December 31, 2014 the Company issued an aggregate of 100,000 shares for consulting services rendered in conjunction with store management and they were valued at $30,000 using the closing price on the date the shares were granted.

  

As of June 30, 2015, the Company had 50,220,000 shares of its common stock issued and outstanding.

 

 

NOTE 5 – Preferred Stock

 

The total number of preferred shares authorized that may be issued by the Company is 25,000,000 shares with a par value of $0.0001 per share.

 

As of June 30, 2015, the Company had no shares of its preferred stock issued and outstanding.

 

 

 

NOTE 6 – Income Taxes

 

The provision (benefit) for income taxes for the period from February 23, 2011 (inception) June 30, 2015 was as follows, assuming a 35 percent effective tax rate:

  

		June 30, 2015				For the year ended 12/31/14
Current tax provision:
Federal
Taxable income		$	—			$	—
Total current tax provision		$	—			$	—
Deferred tax provision:
Federal
Loss carryforwards		$	333,842			$	134,432
Change in valuation allowance			(333,842	)			(134,432	)
Total deferred tax provision		$	—			$	—

 

As of June 30, 2015, the Company had approximately $953,834 in tax loss carryforwards that can be utilized in future periods to reduce taxable income through 2032.

 

The Company provided a valuation allowance equal to the deferred income tax assets through June 30, 2015 because it is not presently known whether future taxable income will be sufficient to utilize the tax loss carryforwards.

 

The Company has no uncertain tax positions.

 

NOTE 7 – Change of Control

 

On March 27, 2014 the shareholders of Med-Cannabis Pharma, Inc. sold their shares, 210,000,000, to Big Sky Oil, Inc. and another investor, resulting in a change of control.

 

On July 28, 2014, Big Sky Oil, Inc., the majority shareholder of Med-Cannabis Pharma Inc. (the “Company”), returned to the Company’s treasury 159,930,000 shares of the Company’s common stock it had purchased from prior management. Big Sky agreed to return these shares to the treasury for use in future possible issuances by the Company.

 

NOTE 8 – Related Party Transactions

 

The Company operates under an agreement with Bendor Investments, LTD, a related party, under which MCPI receives a fee for managing Bendor’s retail stores.

 

South Beach Live, Inc. a related party directly transferred 1,000,000 shares of its MCPI stock to consultants in return for services to the Company. South Beach does not expect repayment and this transaction was treated as donated capital.

 

As June 30, 2015 the Company had a line-of-credit (”LOC”) to a related party stockholder in the amount of $692,227, with interest at 10% annually. This LOC was entered into on July 28, 2014 and replaced the shareholder note that was assumed during the change of control transaction. During the three months ended June 30, 2015 Interest expense on the LOC was $14,337.

 

$51,757 of the Company’s accounts payable and accrued expenses are to related parties. $24,923 of this amount was assumed when current management took control.

 

In the change of control agreements dated March 27, 2014, $1,806 of related party debt was forgiven by a former shareholder.

 

  

 

NOTE 9 – Recent Accounting Pronouncements

 

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201416—Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update do not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. That is, an entity will continue to evaluate whether the economic characteristics and risks of the embedded derivative feature are clearly and closely related to those of the host contract, among other relevant criteria. The amendments clarify how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.

 

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201417—Business Combinations (Topic 805): Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments in this Update are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-in-control event occurred already have been issued or made available to be issued, the application of this guidance would be a change in accounting principle.

On August 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements – Going Concerns (Subtopic 205-40): Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements from the Company.

 

 

In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The new guidance requires that share-based compensation that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards and that could be achieved after an employee completes the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation costs should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this Update either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on our financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-10: Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements of development stage entities. The amendments in this update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public companies, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have a material impact on our financial position or results of operations.

Besides what’s noted above the Company does not expect the impact of recent accounting pronouncements to have a material effect on the Company’s financial statements.

 

NOTE 10 – Subsequent Events

 

On July 8, 2015, Med-Cannabis Pharma, Inc. (the “Company”), through its wholly owned subsidiary, High Desert MMJ, Inc. (“High Desert”), an Oregon corporation, has entered into a joint venture agreement with Royal Tree Organics, whereby the parties will seek to develop and grow medical marijuana plants through an entity to be known as Emerald Mountain Organics. As part of the proposed joint venture, Emerald Mountain Organics has entered into a commercial lease for premises in Cottage Grove, Oregon from which to operate the venture.

On August 7, 2015, Med-Cannabis Pharma, Inc. (the “Company”) entered into a non-binding letter of intent to purchase World of Weed, Inc., a Colorado corporation, which operates medical marijuana grow facilities and operates medical and recreational marijuana sales facilities in Colorado. No definitive agreement has yet been executed by the parties and the closing of the transaction is subject to due diligence review and other terms and conditions to be negotiated by and between the parties.

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

We are a corporation with limited operations. Our independent registered public accounting firm has issued a going concern opinion in their audit report dated December 31, 2014, which can be found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 14, 2015. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. Accordingly, we must raise additional cash to sustain our limited operations.

 

We presently are exploring other such sources of funding, including raising funds through a second public offering, a private placement of securities, or loans. If we are unable to raise this additional funding, we will either have to suspend operations until we do raise the cash or cease operations entirely.

 

The following discussion should be read in conjunction with our Financial Statements and the notes thereto and the other information included in this Quarterly Report as filed with the SEC on Form 10-Q.

 

Limited Operating History; Need for Additional Capital

 

There is limited historical financial information about us upon which to base an evaluation of our performance. We remain in the start-up stage of operations and have only begun to generate nominal revenue. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns, such as increases in marketing costs, increases in administration expenditures associated with daily operations, increases in accounting and audit fees, and increases in legal fees related to filings and regulatory compliance.

  

Currently, we do not have any arrangements for additional financing. We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop, or expand our operations. Equity financing could result in additional dilution to existing shareholders.

 

Plan of Operations

 

The medical marijuana dispensaries, which are currently in operations legally within the states that medical marijuana has been approved and is legal. Currently the Company has operating and is negotiating with existing dispensaries in Oregon.

The company intends to further expand by acquiring or opening medical marijuana dispensaries in locations where an acquisition is not readily available such as states where medical marijuana has been newly legalized. The new locations will be based on medicinal demand and location analysis to support maximum potential of success.

The Company currently has corporate offices in Bend, Oregon.

 

 

 

Results of Operations

 

Three months Ended June 30, 2015 and 2014

 

Revenues. We generated revenues of $10,000 during the three months ended June 30, 2015compared to $0 for the same period a year ago.

 

Gross Profit. Our gross profit was $10,000 and $0 during the three months ended June 30, 2015 and for the same period a year ago, respectively.

  

Operating Expenses. Our total operating expenses for the three months ended June 30, 2015 were $116,134, which is a $63,919 or 122%,increase compared to operating expenses of $52,215 for the same period a year ago. The increase in expenses was primarily attributable to increased general and administrative cost from arising from more personnel, paying previously unpaid personnel, and increased accounting costs.

 

Income (Loss) From Operations. We had a loss from operations of $106,134 for the three months ended June 30, 2015 compared to an operating loss of $52,215 for the same period a year ago, which represented a $53,919 increase in operating loss.

   

Other income (expenses). During the three months ended June 30, 2015 we recorded $14,337 interest, compared to $2,655 the same period a year ago. The interest expense is comprised of interest payable related to line-of-credit interest and notes outstanding payable to a related party. In increase is due to higher balances outstanding.

 

Net Income (Loss). We had a net loss of $120,471 for the three months ended June 30, 2015 compared to a net loss of $54,870 for the same period a year ago, which represented an increase of $65,601, in net loss.  

  

Total Stockholders’ Deficit. Our stockholders’ deficit was $601,117 as of June 30, 2015.

 

Six months Ended June 30, 2015 and 2014

 

Revenues. We generated revenues of $10,000 during the six months ended June 30, 2015compared to $0 for the same period a year ago.

 

Gross Profit. Our gross profit was $10,000 and $0 during the Six months ended June 30, 2015 and for the same period a year ago, respectively.

  

Operating Expenses. Our total operating expenses for the six months ended June 30, 2015 were $566,591, which is a $502,151 or 779.3%,increase compared to operating expenses of $64,440 for the same period a year ago. The increase in expenses was primarily attributable to increased general and administrative cost from arising from more personnel, paying previously unpaid personnel, and increased accounting costs.

 

Income (Loss) From Operations. We had a loss from operations of $556,591 for the six months ended June 30, 2015 compared to an operating loss of $64,440 for the same period a year ago, which represented a $492,151 increase in operating loss.

 

 

   

Other income (expenses). During the six months ended June 30, 2015 we recorded $23,152 interest, compared to $4,109 the same period a year ago. The interest expense is comprised of interest payable related to line-of-credit interest and notes outstanding payable to a related party. In increase is due to higher balances outstanding.

 

Net Income (Loss). We had a net loss of $569,743 for the six months ended June 30, 2015 compared to a net loss of $68,549 for the same period a year ago, which represented an increase of $501,194, in net loss.  

 

Liquidity and Capital Resources

 

As June 30, 2015, we had $155,651 of assets. Our total liabilities were $756,828, which consisted of accounts payable of $47,328, accrued expenses of $17,273 and a line-of-credit aggregating $ to a related party. The LOC has a 10% annual interest rate. Further, we had no external credit facilities (i.e. bank loans, revolving lines of credit, etc.).

 

We expect to incur continued losses over the next 12 months, possibly even longer. We believe that we need at least $150,000 in additional funding to commence operations and meet our minimal working capital requirements over the next 12 months.

 

We are presently exploring various sources of funding, including raising funds through a secondary public offering, a private placement of our securities, or loans. Without limiting our available options, future equity financings will most likely be through the sale of additional shares of our common stock. It is possible that we could also offer warrants, options and/or rights in conjunction with any future issuances of our common stock. However, we can give no assurance that financing will be made available to us, and if made available to us, in amounts or on terms acceptable to us. If we cannot secure adequate financing, we may be forced to cease operations and you will lose your entire investment.

 

Going Concern Consideration

 

Our independent registered public accounting firm has issued a going concern opinion in their audit report dated May 13 , 2015, which can be found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 14, 2015. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next 12 months. Our financial statements found within this Quarterly Report on Form 10-Q and the aforementioned Annual Report on Form 10-K contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

 

Off –Balance Sheet Operations

 

As of June 30, 2015, we had no off-balance sheet activities or operations.

 

 

  

CRITICAL ACCOUNTING POLICIES

 

The accompanying financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) for financial information and in accordance with the Securities and Exchange Commission’s (“SEC”) Regulation S-X. They reflect all adjustments which are, in the opinion of Med-Cannabis Pharma’s management, necessary for a fair presentation of the financial position and operating results as of and for the three months ended June 30, 2015 and 2014.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported revenues and expenses during the reporting periods. Because of the use of estimates inherent in the financial reporting process, actual results may differ significantly from those estimates.

 

Cash and Cash Equivalents

 

For purposes of the statement of cash flows, Med-Cannabis Pharma considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. As of June 30, 2015, we had $10,360 in cash and equivalents.

 

Fair Value of Financial Instruments

 

ASC 820, “Fair Value Measurements” and ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

 

 

Level		Description
Level 1		Applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.
Level 2		Applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
Level 3		Applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

 

 

 

 

 

 

 

 

[This space intentionally left blank.]

 

 

 

The estimated fair values of the Company’s financial instruments are as follows:

 

		Fair Value Measurement at June 30, 2015 Using:
Description			6/30/15		Quoted Prices In Active Markets For Identical Assets  (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs  (Level 3)
Assets
	Cash and equivalents	$	27,506	$	27,506	$	-	$	-
		$	27,506	$	27,506	$	-	$	-
Liabilities
	Accounts payable	$	47,328	$	47,328	$	-	$	-
	Accrued Expenses		17,273		17,273
	Note payable to stockholder		692,227		692,227		-		-
		$	756,828	$	756,828	$	-	$	-

  

  

  

		Fair Value Measurement at December 31, 2014 Using:
Description			12/31/14		Quoted Prices In Active Markets For Identical Assets  (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs  (Level 3)
Assets
	Cash and equivalents	$	14,463	$	14,463	$	-	$	-
		$	14,463	$	14,476	$	-	$	-
Liabilities
	Accounts payable	$	6,285	$	6,285	$	-	$	-
	Accrued Expenses		26,333		26,333
	Deferred		5,000		5,000		-		-
	Note payable to stockholder		323,579		323,579		-		-
		$	361,197	$	361,197	$	-	$	-

  

Net Loss per Share Calculation

 

Basic net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per shares is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. During the three months ended June 30, 2015 we had no dilutive financial instruments issued or outstanding.

 

 

 

Revenue Recognition

 

Med-Cannabis Pharma follows the guidance of FASB ASC Topic 605 for revenue recognition. In general, Med-Cannabis Pharma recognizes revenue when (1) the price is fixed and determinable, (2) persuasive evidence of an arrangement exists, (3) the service has been provided, and (4) collectability is reasonably assured.

 

Med-Cannabis Pharma generates revenue from managing the operations of Medical Marijuana dispensaries owned by others.

 

Income Taxes

 

We account for income taxes pursuant to FASB ASC 740, Income Taxes. Under FASB ASC 740-10-25, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

 

We maintain a valuation allowance with respect to deferred tax assets. Med-Cannabis Pharma establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration Med-Cannabis Pharma’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

 

Changes in circumstances, such as Med-Cannabis Pharma generating taxable income, could cause a change in judgment about its ability to realize the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

 

Recently Issued Accounting Pronouncements

  

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201416—Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update do not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. That is, an entity will continue to evaluate whether the economic characteristics and risks of the embedded derivative feature are clearly and closely related to those of the host contract, among other relevant criteria. The amendments clarify how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The effects of initially adopting the amendments in this Update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods.

On November 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 201417—Business Combinations (Topic 805): Pushdown Accounting (a consensus of the FASB Emerging Issues Task Force). The amendments in this Update provide an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The amendments in this Update are effective on November 18, 2014. After the effective date, an acquired entity can make an election to apply the guidance to future change-in-control events or to its most recent change-in-control event. However, if the financial statements for the period in which the most recent change-in-control event occurred already have been issued or made available to be issued, the application of this guidance would be a change in accounting principle.

 

On August 2014, The Financial Accounting Standards Board (FASB) issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements – Going Concerns (Subtopic 205-40): Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-10, “Development Stage Entities”. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the ASC thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in this update are applied retrospectively. The adoption of ASU 2014-10 removed the development stage entity financial reporting requirements from the Company.

In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The new guidance requires that share-based compensation that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards and that could be achieved after an employee completes the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation costs should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This new guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this Update either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on our financial position or results of operations. In June 2014, the FASB issued ASU No. 2014-10: Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation , to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements of development stage entities. The amendments in this update remove all incremental financial reporting requirements from U.S. GAAP for development stage entities, thereby improving financial reporting by eliminating the cost and complexity associated with providing that information. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public companies, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have a material impact on our financial position or results of operations.

Besides what’s noted above the Company does not expect the impact of recent accounting pronouncements to have a material effect on the Company’s financial statements.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable since we are a smaller reporting company.

 

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation under the supervision and with the participation of our sole officer and director, Gracie Moreno, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange Act).

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be presented or detected on a timely basis.

 

Based on management’s assessment, we have concluded that, as June 30, 2015, our disclosure controls and procedures were not effective in timely alerting management to the material information relating to us required to be included in our annual and interim filings with the SEC.

 

  

Management has concluded that our disclosure controls and procedures had the following material weaknesses:

 

• We were unable to maintain any segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency has not resulted in any audit adjustments to our interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties;

• Med-Cannabis Pharma lacks sufficient resources to perform the internal audit function and does not have an Audit Committee;

• We do not have an independent Board of Directors, nor do we have a board member designated as an independent financial expert to Med-Cannabis Pharma. The Board of Directors is comprised of three (3) members, two of whom also serves as Med-Cannabis Pharma’s sole executive officer and a vice president/store manager.. As a result, there is a lack of independent oversight of the management team, lack of independent review of our operating and financial results, and lack of independent review of disclosures made by Med-Cannabis Pharma; and

• Documentation of all proper accounting procedures is not yet complete.

These weaknesses have existed since our inception and, as of June 30, 2015, have not been remedied.

 

 

 

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned material weaknesses, including, but not limited to, the following:

 

• Considering the engagement of consultants to assist in ensuring that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures;

• Hiring additional qualified financial personnel, including a Chief Financial Officer, on a full-time basis;

• Expanding our current board of directors to include additional independent individuals willing to perform directorial functions; and

• Increasing our workforce in preparation for exiting the development stage and commencing revenue producing operations.

Since the recited remedial actions will require that we hire or engage additional personnel, these material weaknesses may not be overcome in the near-term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the limited advice of outside professionals and consultants.

 

Changes in Controls and Procedures

 

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

PART II

 

Item 1. Legal Proceedings

 

No officer, director, or persons nominated for these positions, and no promoter or significant employee (current or former) of our corporation has been involved in legal proceedings that would be material to an evaluation of our management. We are not aware of any pending or threatened legal proceedings involving Med-Cannabis Pharma, Inc.

 

During the past ten (10) years, Gracie Moreno has not been the subject of the following events:

 

1)

Any bankruptcy petition filed by or against any business of which Ms. Moreno was a general partner or executive officer either at the time of the bankruptcy or within two (2) years prior to that time;

 

2)

Any conviction in a criminal proceeding or being subject to a pending criminal proceeding;

 

3)

An order, judgment, or decree, not subsequently reversed, suspended or vacated, or any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting Ms. Moreno’s involvement in any type of business, securities or banking activities; and

 

4)

Found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Future Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

 

Item 1A. Risk Factors

 

Not applicable since we are a smaller reporting company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Default Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None.

 

 

 

Item 6. Exhibits

 

 

Exhibit Number		Description of Exhibit
3.1(1)		Articles of Incorporation
3.2(1)		Bylaws
3.3(2)		Amendment to Articles of Incorporation
31.1		Section 302 Certifications under Sarbanes-Oxley Act of 2002
32.1		Section 906 Certification under Sarbanes Oxley Act of 2002

 

(1)

Incorporated by our Registration Statement on Form S-1 filed May 3, 2011.

 

	(2)	Incorporated by our Current Report on Form 8-K filed July 1, 2014.

The 8-K’s filed by the Company during the quarter related only to routine course-of-business matters.

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned, thereto duly authorized on this 14th day of August, 2015.

 

	MED-CANNABIS PHARMA, INC.
	By:     /s/ Gracie Moreno
	Gracie Moreno
	President, Chief Executive Officer,
	Principal Executive Officer, and Director
	By:    /s/ Garrett Vogel
	Chief Financial Officer, Principal Accounting Officer,
	Treasurer and Secretary